Comparison of the effects of AcSDKP, thymosin beta4, macrophage inflammatory protein 1alpha and transforming growth factor beta on human leukemic cells.

Defard M, Lemoine FM, Bonnet ML, Baillou C, Isnard F, Najman A, Guigon M

Leukemia & lymphoma1 Nov 1997Cited by 6 (Europe PMC)

PMID9477130DOI10.3109/10428199709058315PepBankPUB-09477130

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Efficacy outcome
In human leukemic cells, thymosin beta‑4 showed an inhibitory effect on proliferation in a few cases, and only at high doses.
In plain wordsIn cells, thymosin beta‑4 slowed the growth of leukemia cells in only a few cases, and only at high doses.
Peptide
Thymosin beta-4 (human)
Outcome
MixedProliferation of leukemic cells (thymidine incorporation)
Study
humann: not reported in source
AML and B-ALL leukemic cells in liquid culture
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Source sentences
Summary
AcSDKP and Tbeta4 showed an inhibitory effect in a few cases but only at high doses
2 context sentences(design, population, supporting numbers)
Summary · context
We have compared the effects of AcSDKP, Thymosin beta4 (Tbeta4), MIP1alpha and TGFbeta on acute myeloid leukemia (AML) and B-lineage acute lymphoid leukemia (B-ALL) cells using liquid cultures in the presence of GM-CSF, IL-3 and SCF for AML cells and IL-3 and IL-7 for ALL cells.
Summary · context
Each molecule was added daily and cell proliferation was evaluated on day 3 by thymidine incorporation.
Report a problemFND-0947713001
02LabIn vitro (cells)Efficacy outcome
The high doses of thymosin beta‑4 that inhibited some leukemic cells were inactive on normal cells.
In plain wordsIn cells, the high doses of thymosin beta‑4 that slowed some leukemia cells did not affect normal cells.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeProliferation of normal cells at high doses
Study
n: not reported in source
Normal cells (type not stated)
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Source sentences
Summary
AcSDKP and Tbeta4 showed an inhibitory effect in a few cases but only at high doses which were inactive on normal cells
2 context sentences(design, population, supporting numbers)
Summary · context
We have compared the effects of AcSDKP, Thymosin beta4 (Tbeta4), MIP1alpha and TGFbeta on acute myeloid leukemia (AML) and B-lineage acute lymphoid leukemia (B-ALL) cells using liquid cultures in the presence of GM-CSF, IL-3 and SCF for AML cells and IL-3 and IL-7 for ALL cells.
Summary · context
Each molecule was added daily and cell proliferation was evaluated on day 3 by thymidine incorporation.
Report a problemFND-0947713002

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.